When a patient is not responding to their TKI therapy, one of the tests we do is an ABL kinase mutation study to determine if the fusion protein has changed its shape making the TKI less effective. We do not do this test at the diagnosis because most patients will not have a mutation out of the gate. They develop during treatment. If you see a mutation, then you can then look to see which medications may be the best fit. The NCCN Guidelines have a nice table that lists which mutation responds to which therapy. There are some mutations where you can pick any of them. There are other mutations that only one or two drugs may work, such as the T315I mutation.For more information on managing your patients with CML, and to participate in an interactive case study in which you’ll be able to make clinical decisions for a patient with CP-CML, please view the activity available here.